Pancreatic cancer targeted therapy breakthrough: daraxonrasib and IL1RAP inhibition
Key Questions
What survival benefit does daraxonrasib show in pancreatic cancer?
In Phase 3, daraxonrasib nearly doubled median survival to 13.2 months versus 6.6 months. The vopimetostat combination achieved a 92% response rate in MTAP-deleted/RAS-mutant disease.
What is the status of IL1RAP inhibition in pancreatic cancer trials?
IL1RAP inhibition is advancing to a neoadjuvant trial combined with chemoimmunotherapy. This targets a novel pathway in metastatic pancreatic cancer.
How does daraxonrasib work as a targeted therapy?
It is a KRAS G12D inhibitor that addresses a key mutation driving pancreatic tumors. Early data support its role in extending survival for patients with limited options.
Daraxonrasib (KRAS G12D inhibitor) nearly doubles median survival (13.2 vs 6.6 months) in Phase 3. Vopimetostat-daraxonrasib combo shows 92% response in MTAP-deleted/RAS-mutant metastatic disease. IL1RAP inhibition moving to neoadjuvant trial with chemoimmunotherapy.